This research aimed to assess both the clinical effectiveness and safety of rosuvastatin therapy in patients diagnosed with hypercholesterolemia and dyslipidemia. The study involved 60 participants treated at the therapeutic unit of Bukhara City Clinical Hospital between 2024 and 2025. Subjects were randomly assigned to two groups: the first group (n=30) received daily doses of rosuvastatin (10–20 mg), while the second group (n=30) underwent lifestyle and dietary interventions without medication. The key parameters analyzed included changes in lipid profiles — specifically total cholesterol, LDL-C, and HDL-C — along with liver enzyme levels to ensure drug safety.

    At baseline, lipid indicators were similar between both groups. After 12 weeks, those treated with rosuvastatin demonstrated marked improvements: total cholesterol levels dropped by 28%, LDL-C was reduced by 44%, and HDL-C rose by 27%, all with statistically significant differences (p < 0.05). The lifestyle-only group did not show meaningful changes in these metrics. The medication was well tolerated overall, with only mild adverse reactions observed in two individuals, none of which required stopping the therapy.

    These results reinforce the established lipid-lowering potential of rosuvastatin and affirm its safety in everyday clinical settings. The study highlights that rosuvastatin therapy yields significantly better improvements in lipid profiles than non-pharmacological measures alone. Therefore, it should be regarded as a key element in the prevention of atherosclerosis and cardiovascular complications, especially for patients at heightened risk. Further extensive, long-term trials are recommended to validate the durability of these benefits and track long-term safety outcomes.

rosuvastatin, hypercholesterolemia, dyslipidemia, atherosclerosis, lipid profile, prevention.

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guidelines on the Management of Blood Cholesterol. Circulation. 2019;139:e1082–e1143.

Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated CRP. N Engl J Med. 2008;359(21):2195–2207.

Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.

Davidson MH. Rosuvastatin: A highly efficacious statin for dyslipidemia. Expert Opin Investig Drugs. 2002;11(1):125–141.

Chapman MJ, et al. Triglyceride-rich lipoproteins and HDL cholesterol in high-risk patients. Eur Heart J. 2011;32(11):1345–1361.